The latest type 2 diabetes (T2D) management guidance from the American Association of Clinical Endocrinology (AACE) covers ...

Novo Nordisk (NVO) stock gains after oral semaglutide pill succeeds in pediatric type 2 diabetes trial. Company targets H2 ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ...

Best known as a type 2 diabetes treatment, metformin is also being investigated for its possible effects on PCOS and ageing.

As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is ...

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new ...

Novo Nordisk's oral GLP-1 pill achieved its main target in a late-stage diabetes study involving children and adolescents ...

Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight loss. Known as “triple-G,” injectable retatrutide levies a triple whammy on the GLP-1, GIP and ...

Novo Nordisk said Wednesday that an experimental drug it is developing with Chinese pharmaceutical company The United Bio-Technology (Hengqin) Co. showed "positive" results with a mean body weight ...